| The role of the new beta-blockers in treating cardiovascular disease. | |
| | |
MedLine Citation:
|
PMID: 16373195 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The beta-adrenergic receptor blockers play an important role in the management of cardiovascular disease, including hypertension and chronic heart failure. However, concerns regarding safety and tolerability with currently available agents can limit their use. The beta-blockers vary with regard to several pharmacologic properties, including beta1/beta2 selectivity, intrinsic sympathomimetic activity, and, with the newest beta-blockers, vasodilation. These pharmacologic differences may result in clinically important differences in tolerability and hemodynamic properties. Nebivolol is a novel beta-blocker with both a greater degree of selectivity for beta1-adrenergic receptors than other agents in this class and an ability to stimulate endothelial nitric oxide production, leading to vasodilation and other potential clinical effects. Published randomized, controlled, multicenter studies with nebivolol have shown that once-daily treatment significantly reduces systolic and diastolic blood pressure in patients with mild-to-moderate hypertension, compared with placebo, in a dose-dependent manner, and is well tolerated, with an adverse event profile similar to that of placebo. When compared with other beta-blockers as well as with other antihypertensive classes of agents in head-to-head trials, nebivolol demonstrated similar antihypertensive efficacy and a lower incidence of adverse events. Nebivolol has also been shown to significantly reduce morbidity and mortality in a large population of elderly patients with chronic heart failure, independent of left ventricular ejection fraction. Nebivolol is currently available in Europe for the management of hypertension and is expected to be available soon in the United States. |
| | |
Authors:
|
Michael A Weber |
Related Documents
:
|
14504635 - Value of propranolol-induced heart rate and blood pressure changes in predicting result... 2034475 - Do beta-adrenergic blockade and sleep state affect cardiorespiratory control in neonata... 2409395 - Changes in cardiovascular responsiveness caused by age and high blood pressure: implica... 6488695 - Chronic propranolol treatment decreases pulmonary artery pressure in conscious dogs. 22689545 - Unusual cause of acquired brain injury. 11812705 - The effect of nitrous oxide on jugular bulb oxygen saturation during remifentanil plus ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: American journal of hypertension Volume: 18 ISSN: 0895-7061 ISO Abbreviation: Am. J. Hypertens. Publication Date: 2005 Dec |
Date Detail:
|
Created Date: 2005-12-23 Completed Date: 2006-02-03 Revised Date: 2009-02-24 |
Medline Journal Info:
|
Nlm Unique ID: 8803676 Medline TA: Am J Hypertens Country: United States |
Other Details:
|
Languages: eng Pagination: 169S-176S Citation Subset: IM |
Affiliation:
|
Department of Medicine, State University of New York, Brooklyn, New York, USA. minskyja@cs.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adrenergic beta-Antagonists / therapeutic use* Adult Aged Antihypertensive Agents / therapeutic use* Atenolol / therapeutic use Benzopyrans / adverse effects, therapeutic use* Cardiovascular Diseases / drug therapy* Clinical Trials as Topic Enalapril / therapeutic use Ethanolamines / adverse effects, therapeutic use* Female Heart Failure / drug therapy Hemodynamics / drug effects Humans Hypertension / drug therapy Labetalol / therapeutic use Losartan / therapeutic use Male Metoprolol / adverse effects, therapeutic use Middle Aged Nifedipine / therapeutic use Receptors, Adrenergic, beta-1 / drug effects Receptors, Adrenergic, beta-2 / drug effects Sympathomimetics / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Benzopyrans; 0/Ethanolamines; 0/Receptors, Adrenergic, beta-1; 0/Receptors, Adrenergic, beta-2; 0/Sympathomimetics; 114798-26-4/Losartan; 21829-25-4/Nifedipine; 29122-68-7/Atenolol; 36894-69-6/Labetalol; 37350-58-6/Metoprolol; 75847-73-3/Enalapril; 99200-09-6/nebivolol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of beta-blockers as a cornerstone of cardiovascular therapy.
Next Document: Exploring vascular benefits of endothelium-derived nitric oxide.